Canaccord Genuity Maintains a 'Hold' on Dolby Laboratories (DLB); Updating Model
Tweet
Share
E-mailGet Alerts DLB Hot Sheet
Price: $62.39 +0.03%
Rating Summary:
6 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
6 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Canaccord Genuity maintains a 'Hold' on Dolby Laboratories (NYSE: DLB) price target from $36 to $42.
Analyst, Jeff Rath, said, "We maintain our rating and have increased our target to $42 to account for the increased stock buy-back program and our refined assumptions on the impact of Win8 launch. Broader media consumption trends are beginning a clear secular shift away from optical disk, which will likely create significant challenges for DLB in coming years, in our opinion."
For an analyst ratings summary and ratings history on Dolby Laboratories click here. For more ratings news on Dolby Laboratories click here.
Shares of Dolby Laboratories closed at $39.33 yesterday.
Analyst, Jeff Rath, said, "We maintain our rating and have increased our target to $42 to account for the increased stock buy-back program and our refined assumptions on the impact of Win8 launch. Broader media consumption trends are beginning a clear secular shift away from optical disk, which will likely create significant challenges for DLB in coming years, in our opinion."
For an analyst ratings summary and ratings history on Dolby Laboratories click here. For more ratings news on Dolby Laboratories click here.
Shares of Dolby Laboratories closed at $39.33 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- Freedom Broker Upgrades Serve Robotics (SERV) to Buy
- BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
